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Abstract
Based on previous ﬁndings for the role of single nucleotide polymorphisms (SNPs) of TNF for the predisposition for bloodstream infections,
this study investigates the role of these SNPs at the promoter positions 376, 308, 238 in infective endocarditis (IE). In a case–control
study, 83 patients with IE and 83 controls were enrolled. Blood genotyping for the presence of G or A alleles of the three SNPs was carried
out using restriction fragment length polymorphisms. Haplotypes were calculated. Patients were mostly infected by Staphylococcus aureus
(32.5%) and by species of enterococci (14.3%) and streptococci (14.3%). Carriage of the minor frequency A alleles at 238 of the promoter
region of TNF was greater than in controls (8.4% versus 1.2%, p 0.003). The presence of any of the three GGA/GAA/AGA haplotypes was
more frequent in patients with IE (OR 8.22, 95CI% 1.8–37.4, p 0.001). After multivariate logistic regression analysis, it was found that the
only factor related to fatal outcome was carriage of the wild-type GGG haplotype (OR, 3.29, 95CI%, 1.05–10.29, p 0.04). GGA, AGA and
GAA haplotypes were more frequent in patients with IE than in controls, suggesting a predisposition for IE and a potential protective role
against fatal outcome, as the wild-type GGG haplotype was independently related with death.
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Introduction
Infective endocarditis (IE) is a severe disease with signiﬁcant
mortality even in the era of cardiovascular surgery and
antimicrobial treatment [1,2]. Microbiology, clinical course of
IE and factors inﬂuencing outcome have been discussed in large
epidemiological studies worldwide [2–10]. Staphylococci and
streptococci have high afﬁnity and adhesion to the cardiac
structures, as already shown through in vitro studies and
experimental animal models for IE [1,11]. Usually these
bacteria interact with platelets, coagulation factors and matrix
molecules on the already damaged tissue surfaces. Vegetations
on valves or other cardiac structures are the characteristic
formation of IE; they emerge as the end result of the dynamic
interaction between host and microorganisms [12]. As a result
of this interaction, a great bulk of pro-inﬂammatory cytokines
is released from cells of the innate immune system, namely
circulating monocytes and tissue macrophages [13]. These
cytokines are encoded by genes that present with subtle
differences from one host to the other, also known as single
nucleotide polymorphisms (SNPs).
One of the most broadly studied cytokine genes is TNF
encoding for tumour necrosis factor-a (TNF-a), which is one of
themajor inducers of pro-inﬂammatory phenomena [13].Τhree
SNPs are well recognized at the promoter region of TNF; a
substitution of guanine by adenine at the 376 position (376
TNFG/A, rs1800750); a substitution of guanine by adenine at the
308 position (308 TNFG/A, rs1800629); and a substitution of
guanine by adenine at the 238 position (238 TNF G/A,
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rs361525). The clinical impact of SNPs is not fully elucidated;
many authors believe that carriage of minor frequency alleles in
any of the above positions of the gene promoter is linked with
predisposition to infections. To this end, many case–control
studies have shown that carriage of theseminor frequency alleles
is linked with susceptibility for early development of ventilator-
associated pneumonia after intubation [14], with HIV infection
[15], and with H1N1-related pneumonia in patients with
predisposing factors like obesity and chronic diseases of the
airways [16]. No data on the role of TNF SNPs exist for the
acquisition of IE. However, SNPs of other inﬂammatory
mediators are reported to impact on the physical course of IE.
SNPs of lipopolysaccharide-binding protein in patients with IE
(c.291 C > T and c.613 A > G) were signiﬁcantly more fre-
quent compared with healthy controls [17]. Recently, SNPs of
TLR2 encoding for Toll-like receptor-2 (TLR2), which is the
major pattern recognition receptor for structures of Gram-
positive bacteria, was found to be signiﬁcantly correlated with IE
in 65 Spanish patients [18]. The TLR2 R753Q co-dominant
(OR = 13.33), recessive (OR = 9.12) and dominant
(OR = 3.65) genotypes showed a positive association with IE
[18]. The above conducted studies that demonstrate a link
between SNPs of the gene encoding for molecules participating
in the inﬂammatory response and IE generates the hypothesis
that SNPs of TNF may also play some role.
This is the ﬁrst study ever conducted trying to investigate the
role of TNF SNPs in the natural course of patients with IE who
were prospectively evaluated at a tertiary reference hospital.
Patients and Methods
Study design
This case–control study was conducted during the period
September 2007 to June 2011. Inclusion criteria for cases were
(1) Caucasian origin; and (2) diagnosis of endocarditis by the
DUKE criteria [19]. Patients with neutropenia, HIV infection
or chronic intake of corticosteroids were excluded. The study
was approved by the Ethics Committee of the ATTIKON
University General Hospital. Each participant completed a
written informed consent, allowing the study’s investigator to
take and store blood sample for DNA extraction and analysis
of TNF SNPs. A similar amount of blood sample was drawn
from 83 healthy Greek blood donors of Caucasian origin after
informed consent. They were well-matched for age, sex and
cardiovascular risk factors and they had a negative history for
IE. The SNPs of TNF of these individuals were used as a control
group. A regression model of statistical analysis of predictors
of outcome was applied via the SPSS.200 statistical software
program (SPSS Inc., Chicago, IL, USA).
Patients’ data collection
Following the participant’s informed consent, data were
recorded as follows: (1) demographics (age, gender, location),
underlying diseases (diabetes mellitus, cardiovascular diseases
including coronary heart disease, renal and liver disease,
immunosuppression), previous history of IE or rheumatic
fever, intravenous drug abusers, prosthetic valve or cardiac
device (pacemaker/deﬁbrillator), valve predisposition for IE
(valve prolapsed, stenosis or bicuspid valve, congenital cardi-
opathy); (2) microbiology of IE (staphylococci, streptococci,
enterococci, fungi and miscellaneous pathogens); and (3)
clinical course of IE: persistent bacteraemia (more than 72 h
despite adequate antimicrobial treatment), time from IE onset
to complications of IE (i.e. valve abscess, peripheral emboli,
stroke, sepsis [20], heart failure NYHA III–IV [21], renal
failure, prosthetic valve dehiscence), cardiac surgery for IE and
mortality. All patients were treated with antibiotics according
to treatment guidelines for IE [22].
Blood collection and genotyping
Two millilitres of whole blood for genotyping analysis was
collected in EDTA and stored at 70°C until processed.
Genomic DNA was extracted by the Purigen Blood Core Kit
C (Qiagen, Hilden, Germany) according to the instructions of
the manufacturer. Typing for the three SNPs of TNF was
performed by PCR on a Sensoquest thermal cycler LabCycler
Gradient using 50 ng of genomic DNA at a ﬁnal volume of
27 lL with 50 mM of MgCl2 (New England Biolabs, Ipswich,
MA, USA), 20 mM of dNTPs (New England Biolabs) and 1 mM
of Taq polymerase (New England Biolabs). Selection of primers
for SNP alleles of the TNF-gene and conditions of PCR were
based on a previous publication [16].
For the –376 (G/A) SNP, a 148-base-pair (bp) fragment was
ampliﬁed with forward primer (5-CCTCAGGACTCAAC
ACAGC-3′) and reverse primer (5′-GGGGACCAGGTCT
GTGGTCTGTTTCCTGTTAA-3′). For the 308 G/A SNP, a
147-bp fragment was ampliﬁed with forward primer 5′-GAG
GCA ATA GGT TTT GAG GGC CAT-3′and reverse primer
5′-GGG ACA CAC AAG CAT CAA G-3′. For –238 G/A SNP
a 165-bp fragment was ampliﬁed with forward primer (5′-CAG
ACCACAGACCTGGTC-3′) and reverse primer (5′-AAG
GATACCCCTCACACTCCCCATCCTCCCGGATC-3′).
All PCR consisted of one initial denaturation phase of 95°C
for 10 min followed by 35 cycles; each cycle consisted of one
annealing step of 94°C for 1 min, one polymerization step of
60°C for 1 min and one elongation step of 72°C for 1 min.
Then another cycle of 72°C for 7 min was carried out before
termination. Ten microlitres of the PCR product was digested
after incubation for 4 h at 37°C with 0.5 U of the restriction
enzyme HpaI for the 376 G/A TNF SNP; NcoI for 308 G/A
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TNF SNP; and BamHΙ for the 238 G/A TNF SNP (New
England BioLabs). Digested PCR products were visualized
following 2% agarose gel electrophoresis and ethidium bro-
mide staining and compared with positive controls. For the
376 G/A TNF SNP, if enzyme digestion yielded one 148-bp
fragment, presence of only A alleles was conﬁrmed; if it yielded
two fragments one of 118 bp and another of 30 bp, presence
of the both A and G alleles was conﬁrmed. For the 308 G/A
TNF SNP, if restriction digestion yielded one 147-bp fragment,
presence of only A alleles was conﬁrmed; if digestion yielded
two fragments, one of 121 bp and another of 26 bp, presence
of both A and G alleles was conﬁrmed. For the 238 G/A TNF
SNP, if digestion yielded one 165-bp fragment, the presence
only of A alleles was conﬁrmed; if digestion yielded two
fragments one of 123 bp and another of 42 bp, then the
presence of both A and G alleles was conﬁrmed. Haplotype
calculations were carried out using UNPHASED [23].
Statistical analysis
Difference in the frequencies of TNF SNP distribution between
patients with IE and healthy controls was the primary end-
point of the study. The impact of SNPs in the natural course of
IE was the secondary end-point of the study. To assess the
primary end-point, frequencies of TNF SNPs and of carriage of
alleles between groups were compared by the chi-squared and
by the Fischer’s exact tests. Multiple step-wise logistic
regression analysis was performed with advent of mortality
as a dependent variable and age, presence of risk factors for IE,
persisting bacteraemia and carriage of any of the three studied
SNP alleles as independent variables. The OR and 95% CI were
estimated and any value of p <0.05 was considered signiﬁcant
after adjustment for multiple comparisons.
Results
Clinical characteristics of patients with IE
Demographic characteristics of enrolled patients are shown in
Table 1. Left-sided IE accounted for 74.4% of cases. Intrave-
nous drug abusers (n = 11) presented mostly with right-sided
IE (n = 9). Prosthetic valve IE and intracardiac device IE were
found in 22.9% and 10.8% of cases, respectively. Microbiolog-
ical documentation of IE conﬁrmed Staphylococcus aureus
(methicillin-resistant n = 7, methicillin susceptible n = 18) as
the predominant pathogen (32.5%), followed by enterococci
(14.3%) and viridans streptococci (14.3%). Persistent bacter-
aemia was detected in 45% of patients. Any complication
related to IE was found in 94% (n = 74) of patients. Mostly, it
was severe valve insufﬁciency requiring cardiac surgery (42.8%,
n = 33), which was performed in 45% of the patients of the
study. Mortality was assessed in 20.5% of patients (Table 1).
Distribution of A alleles of TNF between IE and control
patients
The major and minor allele frequencies of the studied SNPs
are shown in Table 2. Alleles for all SNPs were in Hardy–
Weinberg equilibrium. Distribution of A alleles of the
promoter region 238 of TNF was signiﬁcantly greater in
patients with IE compared with the control group (8.4% versus
1.2%, p =0.003). It was possible to identify ﬁve different
haplotypes. Their distribution in both patients and healthy
controls is shown in Table 3. The presence of GGA/GAA/
AGA haplotypes is connected to a considerable risk for IE
(p =0.001, OR 8.22, 95% CI 1.8–37.4).
Logistic regression analysis of factors related to unfavourable
outcome of IE
It was then assessed what the importance of the increased
frequency haplotypes other than GGG in the physical course
of IE may be. To this end, step-wise multiple logistic regression
analysis was carried out to investigate the impact of various
factors on mortality from IE (Table 4). Carriage of the GGG
wild-type haplotype was independently associated with unfa-
vourable outcome (p =0.04, OR 3.29). Neither age nor
TABLE 1. Demographics and clinical characteristics of 83
patients with infective endocarditis (IE)
Characteristic Value
Age, mean ( SD) years 58.5 (17.4)
Male (n, %), 56 (67.5)
Comorbidities (n, %) 67 (80.7)
Type 2 diabetes mellitus 17 (20.5)
Coronary heart disease 23
IE risk factorsa (n, %) 54 (65)
Prosthetic valve (n, %) 19 (22.9)
Intracardiac implantable device (n, %) 9 (10.8)
Left-sided IE (n, %) 62 (74.7)
Persistent bacteraemia (n, %) 37 (44.6)
Pathogens (n, %) 77 (92.7)
Staphylococcus aureus 25 (30.1)
Coagulase-negative staphylococci 8 (9.6)
Viridans streptococci 11 (13.3)
Other streptococci 5 (6.0)
Enterococci 11 (13.3)
Candida spp. 5 (6.0)
Gram-negative bacteria 5 (6.0)
Coxiella burnetii 5 (6.0)
Others (Brucella spp., Corynobacterium sp.) 2 (2.4)
Any complication (n, %) 78 (94)
Peripheral emboli 30 (36.1)
Stroke 12 (14.5)
Pulmonary embolism 10 (12.0)
Severe valve insufﬁciency 34 (40.9)
Heart failure NYHA III–IV 32 (38.6)
Valve abscess 17 (20.5)
Renal failure 17 (20.5)
Severe sepsis/shock 9 (10.8)
Time from presentation of IE to
complications (months, median (range))
0.5 (0–5)
Cardiac surgery for IE (n, %) 40 (48.2)
Mortality (n, %) 17 (20.5)
aRisk: history of IE, history of rheumatic fever, native valve predisposition,
pacemaker/deﬁbrillator, prosthetic valve, homografts, intravenous drug abusers.
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persistent bacteraemia nor risk factors for IE were found to
signiﬁcantly inﬂuence mortality in this multivariate analysis
model.
Discussion
This is the ﬁrst time that TNF haplotypes were studied in
patients with deﬁnite IE. Calculations showed that GGA, AGA
and GAA haplotypes were rare in the control population. On
the contrary, they were relatively frequent in patients with IE,
suggesting that carriage of these haplotypes may predispose to
IE. Surprisingly, in patients with IE, carriage of the GGG wild-
type haplotype was related to the complications of IE.
Therefore, it can be proposed that the presence of TNF
haplotypes other than the wild type GGG might protect from
complications of IE.
The importance of the studied SNPs in the physical course
of IE may be related with the key role of TNF in the
inﬂammatory response against antigenic stimuli [24]. It is
proposed that cytokine response and clinical presentation
could be signiﬁcantly impaired by the cytokine gene SNPs in
patients with ventilator-associated pneumonia [14]. TNF SNPs,
especially at the 308 position of the gene promoter, have
been largely investigated for a potential inﬂuence on the
pathogenesis and clinical course of autoimmune and infectious
diseases, yielding contradictory results [25]. No relationship
between carriage of minor frequency alleles and TNF-a blood
levels after ex vivo stimulation by endotoxin has been
established [26]. The presence of the 238 G/A TNF SNP
was shown to be related to moderate control of viraemia in
HIV-infected patients [15].
Cardiac disease, which potentially inﬂuences the outcome
of IE, is not deﬁnitely related to the presence of TNF SNPs.
Common TNF polymorphisms were not associated with
increased susceptibility to coronary heart disease [27], a
ﬁnding conﬁrmed by a European ancestry for ischaemic heart
disease [28]. However, in a Korean population, 308 G/A TNF
SNP predisposes to susceptibility to stroke [29]. It is not clear
if an association between TNF gene polymorphisms and
susceptibility to cardiovascular events exists; genetic predis-
position to cardiovascular risk is multi-factorial including other
pathways of thrombosis and inﬂammation as well as environ-
mental factors [30]. The studied population presents with
most of the worldwide accepted characteristics of IE [31];
namely (1) comorbidities; (2) persistent bacteraemia; (3)
Gram-positive cocci as the main pathogens; (4) carriage of
prosthetic devices; (5) high rate of complications requiring
surgery; and (6) high mortality rates associated with well-
deﬁned risk factors [2,4,8]. In a recent study comparing
genomics of S. aureus isolates from patients with IE and from
patients with soft tissue infections, cna gene, map/eap genes
and toxin genes (tst, sei) were independently associated with IE
[32]. The S. aureus eap gene encodes for proteins that
stimulate in vitro the release of TNF-a by human monocytes;
this in turn enhanced the adhesion of S. aureus to endothelial
cells [33].
Speciﬁc microbial genome expression determines the
natural course of IE. In contrast, animal or human genes might
TABLE 2. Distribution of single nucleotide polymorphisms
(SNPs) at the promoter region of TNF of 83 patients with
infective endocarditis (IE) and of 83 healthy controls well-





(n = 83) IE (n = 83)
p of
comparisons
376 G/A GG 82 (98.8) 82 (98.8)
GA 1 (1.2) 1 (1.2) 0.752
rs1800750 AA 0 (0) 0 (0)
G allele 165 (99.4) 165 (99.4) 0.752
A allele 1 (0.6) 1 (0.6)
308 G/A GG 70 (84.3) 68 (81.9)
GA 12 (14.5) 13 (15.7) 0.818
rs1800629 AA 1 (1.2) 2 (2.4)
G allele 152 (91.6) 149 (89.8) 0.707
A allele 14 (8.4) 17 (10.2)
238 G/A GG 81 (97.6) 69 (83.1)
GA 2 (2.4) 14 (16.9) 0.003
rs361525 AA 0 (0) 0 (0)
G allele 164 (98.8) 152 (91.6) 0.003
A allele 2 (1.2) 14 (8.4)
p values are given after adjustment for multiple comparisons.
TABLE 3. Distribution of haplotypes of TNF among 83
patients with infective endocarditis (IE) and 83 healthy
controls well-matched for age and gender
Haplotype Controls (n, %) IE (n, %) p OR (95% CI)
GGG 68 (81.9) 58 (69.9) 0.51 (0.24–1.06)
GAG 13 (15.7) 11 (13.3) 0.82 (0.34–1.99)
GGA 1 (1.2) 10 (12.0) 0.010 11.23 (1.40–89.88)
GAA 0 (0) 4 (4.8) a
AGA 1 (1.2) 0 (0) a
Grouping for haplotypes
GGG or GAG 81 (97.6) 69 (83.1)
GGA or GAA
or AGA
2 (2.4) 14 (16.9) 0.001 8.22 (1.80–37.42)
Calculated haplotypes are composed of rs1800750, rs1800629, rs361525.
aOR and 95% CI could not be calculated because some groups had nil values.
TABLE 4. Step-wise multiple logistic regression analysis of
variables that might inﬂuence mortality in 83 patients with
infective endocarditis (IE)
OR 95% CI p
Risk for IEa 0.54 0.52–1.95 0.351
Age 1.02 0.98–1.05 0.304
Persistent bacteraemia 1.94 0.59–6.36 0.270
GGG haplotype 3.29 1.05–10.29 0.041
aRisk: history of IE, history of rheumatic fever, native valve predisposition,
pacemaker, prosthetic valve, homografts, intravenous drug abuser.
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be involved in the pathogenesis of the disease in a complex
host–microorganism interaction. In an experimental animal
model of S. aureus IE, methicillin-susceptible and methicillin-
resistant S. aureus induced a different pattern of TNF-a
stimulation through a TLR4-independent mechanism, leading
to shorter survival for the methicillin-susceptible S. aureus
group [34]. It is postulated that some proteins expressed in IE
might be useful as predictors of prognostic biomarkers of the
disease. For example, matrix metalloproteins are enzymes
involved in tissue degradation and remodelling of IE vegeta-
tions. Circulating serum metalloproteinase-9 (MMP-9) was
correlated with embolic events in patients with IE [35]. Host
response and the role of gene expression in multiple pathways
in IE have been studied in a genomic microarray analysis of
patients with IE. A speciﬁc transcriptional programme of up
and down gene regulation was assessed in patients with IE and
compared with healthy controls [36]. The expression of genes
encoding for S100 calcium binding A11 (S100A11) protein and
for the receptor RAGE of advanced glucation endproducts was
signiﬁcantly increased in patients with IE. Moreover, the
upregulation of the aquaporin-9 gene (AQP9) was signiﬁcantly
associated with acute heart failure in patients with IE, making it
a potential prognostic marker of this severe, even lethal, IE
complication [36]. Regarding polymorphisms of genes encod-
ing several proteins in IE, SNPs of lipopolysaccharide-binding
protein and TLR2 were predominant in patients with IE
compared with controls, but their clinical signiﬁcance is
unclear [17,18]. In our study, carriage of the common
haplotypes GGG and GAG was related with complications
of IE, suggesting a prognostic role for these haplotypes.
Current results underscore the need to study the SNPs of
other genes encoding for other inﬂammatory mediators in IE.
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